Abstract
Dosimetric parameters for prostate brachytherapy have been correlated with cancer control rate as well as toxicity. D90 has the most data correlating it with cancer control. The ABS recommends post-implant quality assurance (QA) computed tomographic (CT) scans approximately one month after the procedure to verify proper dosimetry. With short half-life isotopes such as Cesium-131 (9.7 days), this one month CT may not account for volume changes from temporary prostatic edema during the majority of the dose deposition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
